PL-3994 for Acute Asthma and Other Pulmonary Indications
PL-3994, discovered and developed by scientists at Palatin Technologies, is a natriuretic peptide receptor A (NPRA) agonist compound under development for acute asthma and other pulmonary indications. PL-3994 has successfully completed Phase 1 safety trials.
PL-3994 is a synthetic molecule, incorporating a novel and proprietary amino acid mimetic developed by Palatin Technologies. PL-3994 has an extended half-life, with reduced affinity for natriuretic peptide clearance receptors and increased resistance to neutral endopeptidase, an endogenous enzyme that degrades natriuretic peptides. The result is a drug with improved pharmacokinetic and pharmacodynamic properties.
PL-3994 activates NPR-A, a receptor known to play a role in cardiovascular homeostasis. PL-3994 increases plasma cyclic guanosine monophosphate (cGMP) levels, a pharmacological response consistent with the effects of endogenous (naturally produced) natriuretic peptides on cardiovascular function and smooth muscle relaxation. PL-3994 also decreases activity of the renin-angiotensin-aldosterone system (RAAS), a hormone system that regulates blood pressure and fluid balance.
- For the presentation on the PL-3994 Phase 1 study at the 12th Annual Scientific Meeting of the Heart Failure Society of America, click here.
- For the presentation on the PL-3994 Phase 2a study at the 13th Annual Scientific Meeting of the Heart Failure Society of America, click here.
|
